| Literature DB >> 35725497 |
Mandana AmeliMojarad1, Melika AmeliMojarad1, Alireza Pourmahdian2.
Abstract
BACKGROUND: Breast cancer is one of the most common types of cancer in women worldwide. Anti-apoptotic activity of cancer cells is considered the main reason for drug resistance in BC which reduces the 5-year survival rate of patients and is still considered the main obstacle for cancer therapy. Stigmasterol (SS) is natural phytosterols compound in the plant which has been proved to play an important role to lower cholesterol and inducing anti-inflammatory, and anticancer properties.Entities:
Keywords: Apoptosis; BCL-2; BCL-XL; Breast cancer; Stigmasterol
Mesh:
Substances:
Year: 2022 PMID: 35725497 PMCID: PMC9208195 DOI: 10.1186/s40360-022-00578-2
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.605
Primers sequences
| Gene | UniProt ID | Forward | Reverse |
|---|---|---|---|
| BCL2 | P10415 | ||
| BCL-XL | Q07817 | ||
| GAPDH | P04406 |
Fig. 1Gene expression levels of Bcl-2 and Bcl-xl after treatment with 20 µM of SS, in MCF-7 and MCF10A cell line as the control. Data are represented as mean ± SD (* P < 0.05)
Fig. 2The inhibitory role of Stigmasterol (SS) on cell viability and proliferation of BC cells, the Survival rate of MCF-7 enhanced in the response to increased levels of SS. The obtained results are expressed as a percentage (A) and (B) which showed a dose and time-dependent manner. Data are presented as mean ± SD of triplicate experiments that were repeated at least three times
Fig. 3Flow cytometry for detection of apoptosis in the MCF-7 cells treated with SS. The cells were treated with mentioned concentrations and harvested after 72 h for double staining (Annexin V/PI)
Fig. 4Inhibition of tumor size by Stigmasterol (A) Comparison of tumor diameter in Balb/c mouse after treatment, with SS compared to cyclophosphamide as the positive control (B) representee tumor photograph from each group